<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00830349</url>
  </required_header>
  <id_info>
    <org_study_id>01172</org_study_id>
    <nct_id>NCT00830349</nct_id>
  </id_info>
  <brief_title>Risperidone 1 mg Tablet in Healthy Subjects Under Fasting Conditions</brief_title>
  <official_title>Randomized, 2-Way Crossover, Bioequivalence Study of Risperidone 1 mg Tablets and Risperdal 1 mg Tablets Administered as a 1 x 1 mg Tablet in Healthy Subjects Under Fasting Conditions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceuticals USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceuticals USA</source>
  <brief_summary>
    <textblock>
      The objective of this study was to compare the rate and extent of absorption of risperidone 1&#xD;
      mg tablets (test) versus Risperdal® (reference) administered as a 1 x 1 mg tablet under&#xD;
      fasting conditions.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Criteria for Evaluation: FDA Bioequivalence Criteria&#xD;
&#xD;
      Statistical Methods: FDA bioequivalence statistical methods&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">July 2004</completion_date>
  <primary_completion_date type="Actual">July 2001</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Cmax and AUC</measure>
    <time_frame>2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Risperidone 1 mg Tablets</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Risperdal® 1 mg Tablets</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>1 mg Tablet</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Risperidone</intervention_name>
    <description>1 mg Tablets</description>
    <arm_group_label>2</arm_group_label>
    <other_name>Risperdal®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria&#xD;
&#xD;
          -  Subjects will be females and/or males, non-smokers, 18 years of age and older.&#xD;
&#xD;
          -  Subjects should read, sign and date an Informed Consent Form prior to any study&#xD;
             procedure.&#xD;
&#xD;
          -  Female Subjects will be post-menopausal or surgically sterilezed.&#xD;
&#xD;
          -  Post-menopausal status is defined as absence of menses for the past 12 months,&#xD;
&#xD;
          -  Sterile status is defined as hysterectomy, bilateral oophorectomy or tubal ligation at&#xD;
             least 6 months ago.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
        Subjects to whom any of the following applies will be excluded from the study:&#xD;
&#xD;
          -  Clinically significant illnesses within 4 weeks of the administration of study&#xD;
             medication.&#xD;
&#xD;
          -  Clinically significant surgery within 4 weeks prior to the administration of the study&#xD;
             medication.&#xD;
&#xD;
          -  Any history or presence of significant Neurological, hepatic, renal, endocrine,&#xD;
             cardiovascular, pulmonary, hematologic, immunologic, psychiatric or metabolic disease.&#xD;
&#xD;
          -  Any clinically significant abnormality found during medical screening.&#xD;
&#xD;
          -  Any reason which, in the opinion of the medical subinvestigator, would prevent the&#xD;
             subject from participating in the study.&#xD;
&#xD;
          -  Abnormal laboratory tests judged clinically significant.&#xD;
&#xD;
          -  Subjects who do not tolerate venipuncture.&#xD;
&#xD;
          -  Positive urine drug screen at screening.&#xD;
&#xD;
          -  Subjects who use tobacco in any form will not be eligible to participate in this&#xD;
             study. Three months abstinence before screening is required.&#xD;
&#xD;
          -  Positive testing for hepatitis B, hepatitis C or HIV at screening.&#xD;
&#xD;
          -  ECG abnormalities (clinically significant) (PR interval greater than 225 msec or QTc&#xD;
             segment greater than 450 msec) or vital sign abnormalities (systolic blood pressure&#xD;
             lower than 100 or over 160 mmHg, or diastolic blood pressure lower than 60 or over 96;&#xD;
             or heart rate less than 60 bpm) at screening.&#xD;
&#xD;
          -  Subjects with BMI ≥30.0.&#xD;
&#xD;
          -  History of seizures or other predisposing factors.&#xD;
&#xD;
          -  History of significant alcohol abuse within six months of the screening visit or any&#xD;
             indication of the regular use of more than two units of alcohol per day (1 Unit = 150&#xD;
             mL of wine or 360 mL of beer or 45 mL of alcohol 40%).&#xD;
&#xD;
          -  History of drug abuse or use of illegal drugs: use of soft drugs (such as marijuana,&#xD;
             pot) within 3 months of the screening visit or hard drugs (such as cocaine,&#xD;
             phencyclidine (PCP) and crack) within 1 year of the screening visit.&#xD;
&#xD;
          -  History of cardiac disease or family history of cardiac disease.&#xD;
&#xD;
          -  Any food allergy, intolerance, restriction or special diet that, in the opinion of the&#xD;
             medical subinvestigator, contraindicates the subject's participation in this study.&#xD;
&#xD;
          -  History of allergic reactions to risperidone.&#xD;
&#xD;
          -  Use of any drugs known to induce or inhibit hepatic drug metabolism, use of an&#xD;
             investigational drug or participation on an investigation study within 30 days prior&#xD;
             to the administration of the study medication.&#xD;
&#xD;
          -  Use of prescription medication within 14 days prior to administration of study&#xD;
             medication or over-the-counter products within 7 days prior to administration of study&#xD;
             medication, except for topical products without systemic absorption.&#xD;
&#xD;
          -  Donation of plasma (500 mL) within 7 days or donation or significant loss of whole&#xD;
             blood (500 mL) within 56 days prior to administration of the study medication.&#xD;
&#xD;
          -  Positive alcohol breath test at screening.&#xD;
&#xD;
        Additional exclusion criteria for female subjects only:&#xD;
&#xD;
        o Positive urine pregnancy test at screening (performed on all females).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Benoit Girard, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anapharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anapharm Inc.</name>
      <address>
        <city>Sainte-Foy</city>
        <state>Quebec</state>
        <zip>G1V 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <study_first_submitted>January 26, 2009</study_first_submitted>
  <study_first_submitted_qc>January 26, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2009</study_first_posted>
  <last_update_submitted>January 26, 2009</last_update_submitted>
  <last_update_submitted_qc>January 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2009</last_update_posted>
  <keyword>Bioequivalence</keyword>
  <keyword>Healthy Subjects</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Risperidone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

